
KYTX Stock Forecast & Price Target
KYTX Analyst Ratings
Bulls say
Kyverna Therapeutics's positive outlook is supported by increased confidence among key opinion leaders regarding the safety and applicability of its CAR-T therapies in treating myasthenia gravis (MG) and other autoimmune diseases. The company recently raised its probability of approval for KYV-101 in MG to 35% from 25%, bolstered by promising durability and response data from compassionate-use cases, as well as favorable early signals in refractory rheumatoid arthritis (RA) and multiple sclerosis (MS). Additionally, robust performance metrics indicate that KYV-101 is outperforming established therapies, positioning it as a strong candidate in the competitive landscape of immunology and inflammatory indications.
Bears say
Kyverna Therapeutics faces significant challenges that contribute to a negative outlook on its stock. The company has not demonstrated durable responses in patients treated with KYV-101 for lupus nephritis (LN) or myasthenia gravis (MG), raising concerns as the dataset matures. Additionally, there is a risk of failing to generate positive data for KYV-101 in stiff-person syndrome (SPS) and the potential for long-term dilution, which could further weaken investor confidence.
This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KYTX Analyst Forecast & Price Prediction
Start investing in KYTX
Order type
Buy in
Order amount
Est. shares
0 shares